Literature DB >> 35904886

The development of peripheral microvasculopathy with chronic metabolic disease in obese Zucker rats: a retrograde emergence?

Brayden D Halvorson1, Nithin J Menon1, Daniel Goldman1, Stephanie J Frisbee2, Adam G Goodwill3, Joshua T Butcher4, Phoebe A Stapleton5, Steven D Brooks6, Alexandre C d'Audiffret7, Robert W Wiseman8,9, Julian H Lombard10, Robert W Brock11, I Mark Olfert11,12, Paul D Chantler12, Jefferson C Frisbee1.   

Abstract

The study of peripheral vasculopathy with chronic metabolic disease is challenged by divergent contributions from spatial (the level of resolution or specific tissue being studied) and temporal origins (evolution of the developing impairments in time). Over many years of studying the development of skeletal muscle vasculopathy and its functional implications, we may be at the point of presenting an integrated conceptual model that addresses these challenges within the obese Zucker rat (OZR) model. At the early stages of metabolic disease, where systemic markers of elevated cardiovascular disease risk are present, the only evidence of vascular dysfunction is at postcapillary and collecting venules, where leukocyte adhesion/rolling is elevated with impaired venular endothelial function. As metabolic disease severity and duration increases, reduced microvessel density becomes evident as well as increased variability in microvascular hematocrit. Subsequently, hemodynamic impairments to distal arteriolar networks emerge, manifesting as increasing perfusion heterogeneity and impaired arteriolar reactivity. This retrograde "wave of dysfunction" continues, creating a condition wherein deficiencies to the distal arteriolar, capillary, and venular microcirculation stabilize and impairments to proximal arteriolar reactivity, wall mechanics, and perfusion distribution evolve. This proximal arteriolar dysfunction parallels increasing failure in fatigue resistance, hyperemic responses, and O2 uptake within self-perfused skeletal muscle. Taken together, these results present a conceptual model for the retrograde development of peripheral vasculopathy with chronic metabolic disease and provide insight into the timing and targeting of interventional strategies to improve health outcomes.NEW & NOTEWORTHY Working from an established database spanning multiple scales and times, we studied progression of peripheral microvascular dysfunction in chronic metabolic disease. The data implicate the postcapillary venular endothelium as the initiating site for vasculopathy. Indicators of dysfunction, spanning network structures, hemodynamics, vascular reactivity, and perfusion progress in an insidious retrograde manner to present as functional impairments to muscle blood flow and performance much later. The silent vasculopathy progression may provide insight into clinical treatment challenges.

Entities:  

Keywords:  microcirculation; microvascular systems; peripheral vascular disease; rat models of metabolic syndrome; skeletal muscle fatigue

Mesh:

Year:  2022        PMID: 35904886      PMCID: PMC9448278          DOI: 10.1152/ajpheart.00264.2022

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   5.125


  58 in total

1.  Spatial heterogeneity in skeletal muscle microvascular blood flow distribution is increased in the metabolic syndrome.

Authors:  Jefferson C Frisbee; Fan Wu; Adam G Goodwill; Joshua T Butcher; Daniel A Beard
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-07-20       Impact factor: 3.619

2.  Blunted temporal activity of microvascular perfusion heterogeneity in metabolic syndrome: a new attractor for peripheral vascular disease?

Authors:  Joshua T Butcher; Adam G Goodwill; Shyla C Stanley; Jefferson C Frisbee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-21       Impact factor: 4.733

3.  Metabolic adaptation follows contractile dysfunction in the heart of obese Zucker rats fed a high-fat "Western" diet.

Authors:  Mathias Burgmaier; Shiraj Sen; Femi Philip; Christopher R Wilson; Charles C Miller; Martin E Young; Heinrich Taegtmeyer
Journal:  Obesity (Silver Spring)       Date:  2010-01-28       Impact factor: 5.002

4.  Skeletal muscle microvascular and interstitial PO2 from rest to contractions.

Authors:  Daniel M Hirai; Jesse C Craig; Trenton D Colburn; Hiroaki Eshima; Yutaka Kano; William L Sexton; Timothy I Musch; David C Poole
Journal:  J Physiol       Date:  2018-01-30       Impact factor: 5.182

Review 5.  Modeling thrombus formation and growth.

Authors:  Hamid Hosseinzadegan; Danesh K Tafti
Journal:  Biotechnol Bioeng       Date:  2017-06-26       Impact factor: 4.530

6.  Diet-induced renal changes in Zucker rats are ameliorated by the superoxide dismutase mimetic TEMPOL.

Authors:  Philip J Ebenezer; Nithya Mariappan; Carrie M Elks; Masudul Haque; Joseph Francis
Journal:  Obesity (Silver Spring)       Date:  2009-05-07       Impact factor: 5.002

Review 7.  Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation.

Authors:  Jurgen A H R Claassen; Dick H J Thijssen; Ronney B Panerai; Frank M Faraci
Journal:  Physiol Rev       Date:  2021-03-26       Impact factor: 37.312

8.  Experimental animal models of coronary microvascular dysfunction.

Authors:  Oana Sorop; Jens van de Wouw; Selena Chandler; Vahagn Ohanyan; Johnathan D Tune; William M Chilian; Daphne Merkus; Shawn B Bender; Dirk J Duncker
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

Review 9.  Mechanobiology of Microvascular Function and Structure in Health and Disease: Focus on the Coronary Circulation.

Authors:  Maarten M Brandt; Caroline Cheng; Daphne Merkus; Dirk J Duncker; Oana Sorop
Journal:  Front Physiol       Date:  2021-12-23       Impact factor: 4.566

10.  Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome.

Authors:  Stephanie J Frisbee; Sarah S Singh; Dwayne N Jackson; Kent A Lemaster; Samantha A Milde; J Kevin Shoemaker; Jefferson C Frisbee
Journal:  J Am Heart Assoc       Date:  2018-03-26       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.